Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 24 June 2013 | By Louise Zornoza,
Health Canada has released revised clinical trials guidance for sponsors and trial applications explaining the application requirements for comparative bioavailability trials and filing requirements for the importation of clinical trial supplies.
It also includes clarifications to amendment and notification requirements, study termination and closure criteria, application and review processes, and adverse drug reaction reporting criteria as well as format requirements. The Guidance for Clinical Trial Applications (CTAs) is consistent with the new Common Technical Document (CTD) format.
The revised guidance applies to all sponsors (such as industry, academic, contract research organization) conducting the following clinical trials:
The guidance does not apply to Phase IV clinical trials or clinical trials involving medical devices or natural health products except where indicated.
Health Canada: Revised Clinical Trials Guidance
Read all Breaking News from RegLink
Tags: guidance, clinical trials